Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- Acquired Bone Marrow Failure Syndromes
- Lymphoma
- Small Lymphocytic Lymphoma
- MRD Positive Leukemia
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Lymphoblastic Lymphoma
- Burkitt Lymphoma
- Natural Killer Cell Malignancies
- Marginal Zone B Cell Lymphoma
- High Risk Anemia
- Mantle Cell Lymphoma
- Myelofibrosis
- Myelodysplasia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Diffuse Large Cell Non Hodgkins Lymphoma
- Prolymphocytic Leukemia
- Lymphoplasmacytic Lymphoma
- Myeloproliferative Neoplasms
- Follicular Lymphoma
- Refractory Anemia
- Juvenile Myelomonocytic Leukemia
- Multiple Myeloma
- High Grade Non-Hodgkin's Lymphoma, Adult
- Plasma Cell Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 60 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03314974
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Shernan Holtan, MD Masonic Cancer Center, University of Minnesota
Get Well Soon